Posters

No. 1: upcyte® hepatocytes – proliferating and metabolic competent human hepatocytes (Eurotox 2015)

No. 4: Use of upcyte® hepatocytes to predict toxicological outcomes (SOT 2016)

No. 5: Metabolic competent expandable upcyte® hepatocytes enable metabolism studies including CYP2D6 dependent pathways (SOT 2016)

No. 7: Liver organoid formation using differentiated human upcyte® cells (Dechema 3D 2016)

No. 9: Characterization of proliferating hepatocytes as a model system for drug interaction studies and toxicity screenings (Eurotox 2016)

No. 10: Generation of proliferating human liver sinusoidal endothelial cells (upcyte® LSECs) and upcyte® hepatocytes (Eurotox 2016)

No. 11: Generation of expanded primary human cells in large quantities for cell-based screenings (SLAS 2017)

No. 12: Generation of expanded primary hepatocytes in large quantities for for cell based toxicity & metabolism screenings (SLAS/SOT 2017)

No. 13: Detection of cytokeratin 18 in proliferating, primary-like upcyte® hepatocytes to predict drug-induced hepatotoxicity (SOT 2017)

No. 14: Use of upcyte® hepatocytes as a steatosis model on a multi-organ-chip (SOT 2017)

No. 15: Generation of expanded primary human cells (upcyte®) in large quantities for cell-based screenings (European ISSX 2017)

No. 16: Driving primary liver cells into proliferation (European ISSX 2017)

No. 17: Generation of expanded primary hepatocytes for cell based toxicity and metabolism screenings (European ISSX & Gordon Conference 2017)

No. 18: Generation of expanded primary cells for cell-based toxicity and metabolism screenings (Safety & Pharmacology 2017)

No. 19: Generation of proliferating human liver sinusoidal endothelial cells (upcyte® LSECs) (GASL 2018)

No. 21: Facilitated genotoxicity screenings in expanded human upcyte® keratinocytes (SOT 2018)

No. 22: Expanded primary human liver sinusoidal endothelial cells as a tool to complement hepatotoxicity studies (SOT2018)

No. 23: Generation of Expanded Primary Cells for Cell-Based Toxicity andMetabolismScreenings (SLAS 2018)

No. 24: Hepatobiliary transporter expression and functional uptake of substrates in 2D sandwich cultures using upcyte® hepatocytes (please refer to publication)

No. 25: Toxicity assays using expanded liver cells promote the reduction of animal use in pre-clinical research (Eurotox 2018)

No. 26: Liver bud formation using human upcyte® cells (EUSAAT 2018)

No. 28: in vitro organoid model of the human liver sinusoid (Gordon Metabolism 2019)

No. 29: Generation of Expanded Primary Cells for Cell-Based Toxicity and Metabolism Screenings (Eurotox 2019)

No. 30: Expanded primary human liver sinusoidal endothelial cells (upcyte® as a tool to complement in vitro hepatic studies (GASL 2020)

No. 31: Expanded primary human liver sinusoidal endothelial cells (upcyte® LSECs) as a tool for complex hepatotoxicity studies (SOT 2020)

No. 33: Application poster: upcyte® hepatocytes for CYP induction studies

Gaitantzi et al., Universitätsmedizin Mannheim (Mannheim, Germany) – BMP-9 modulates the hepatic responses to LPS (GASL 2020)

Hambruch et al., Phenex Pharmaceuticals (Heidelberg, Germany) – LXR inverse agonists demonstrate liver lipid lowering effects through multiple mechanisms in rodent models of NASH and in human hepatocytes (EASL 2017)

Kroener et al., Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (Stuttgart, Germany) – a multi-level approach to investigate CYP2D6 dependent metabolism of clomiphene (ISSX 2017)

Maalouf et al., Indigo Biosciences (State College, PA, USA) – Validating the gene expression of clinically relevant CYP450 enzymes and transporters in human upcyte® hepatocytes to develop an in vitro predictive tool for DDI (SOT 2017)

Schaefer et al., Boehringer Ingelheim (Biberach, Germany) – Metabolic Capability of Upcyte® Human Hepatocytes in Long-Term Sandwich Culture and Utility for Clearance Prediction (ISSX Korea 2016)

Schaefer et al. II, Boehringer Ingelheim (Biberach, Germany) – Comparison of Primary vs. Proliferative Human Hepatocytes in Long-Term Culture: Metabolic Capability and Usefulness for Clearance Prediction (ISSX Boston 2016)

Bauer et al., Tissuse GmbH (Berlin, Germany) – Towards a multi-organ-chip combining human liver, pancreatic islets, skeletal muscle and kidney equivalenst to study metabolic diseases